title: Statistical model for prediction of hearing loss in patients receiving cisplatin chemotherapy.
abstract: OBJECTIVE
  This statistical model might be used to predict cisplatin-induced hearing loss, particularly in patients undergoing concomitant radiotherapy.
  
  
  OBJECTIVE
  To create a statistical model based on pretreatment hearing thresholds to provide an individual probability for hearing loss from cisplatin therapy and, secondarily, to investigate the use of hearing classification schemes as predictive tools for hearing loss.
  
  
  METHODS
  Retrospective case-control study.
  
  
  METHODS
  Tertiary care medical center.
  
  
  METHODS
  A total of 112 subjects receiving chemotherapy and audiometric evaluation were evaluated for the study. Of these subjects, 31 met inclusion criteria for analysis.
  
  
  METHODS
  The primary outcome measurement was a statistical model providing the probability of hearing loss following the use of cisplatin chemotherapy.
  
  
  RESULTS
  Fifteen of the 31 subjects had significant hearing loss following cisplatin chemotherapy. American Academy of Otolaryngology-Head and Neck Society and Gardner-Robertson hearing classification schemes revealed little change in hearing grades between pretreatment and posttreatment evaluations for subjects with or without hearing loss. The Chang hearing classification scheme could effectively be used as a predictive tool in determining hearing loss with a sensitivity of 73.33%. Pretreatment hearing thresholds were used to generate a statistical model, based on quadratic approximation, to predict hearing loss (C statistic = 0.842, cross-validated = 0.835). The validity of the model improved when only subjects who received concurrent head and neck irradiation were included in the analysis (C statistic = 0.91). A calculated cutoff of 0.45 for predicted probability has a cross-validated sensitivity and specificity of 80%.
  
  
  CONCLUSIONS
  Pretreatment hearing thresholds can be used as a predictive tool for cisplatin-induced hearing loss, particularly with concomitant radiotherapy.
authors: Department of Otolaryngology and Communication Sciences, Medical College of Wisconsin, Milwaukee, WI 53226, USA.
authors: Andrew
authors: A
authors: Johnson
authors: Sergey
authors: S
authors: Tarima
authors: Stuart
authors: S
authors: Wong
authors: David R
authors: DR
authors: Friedland
authors: Christina L
authors: CL
authors: Runge
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001299:Audiometry; D016022:Case-Control Studies; D002945:Cisplatin / Q000009:adverse effects*; D005260:Female; D034381:Hearing Loss / Q000139:chemically induced*; D006801:Humans; D008297:Male; D008875:Middle Aged; D015233:Models, Statistical; D009369:Neoplasms / Q000188:drug therapy*; D011237:Predictive Value of Tests; D012189:Retrospective Studies
chemical_list: D000970:Antineoplastic Agents; D002945:Cisplatin